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MarA and its homologue, RamA, have been implicated in multidrug resistance (MDR). RamA overexpres-
sion in Salmonella enterica serovar Typhimurium and Escherichia coli conferred MDR independently of marA.
Inactivation of ramA did not affect the antibiotic susceptibilities of wild-type S. enterica serovar Typhimurium
or 15 unrelated clinical MDR isolates. Thus, ramA overexpression is not a common MDR mechanism in
Salmonella.
Multiple antibiotic resistance in Salmonella enterica serovar
Typhimurium, an etiologic agent of food-borne enterocolitis in
humans, is becoming a serious health problem. A multiple-
drug-resistant (MDR) phenotype can likely develop in gram-
negative microorganisms by many mechanisms (4); most of
these have been elucidated in Escherichia coli. Among other
mechanisms, an important route involves activation of the mar
locus: MarA, the transcriptional activator of this locus, medi-
ates drug resistance by causing decreased expression of the
porin OmpF and overexpression of the multidrug efflux pump
ArcB (1, 9). Additional genetic mechanisms of MDR have
been proposed. For instance, homologues of MarA, such as
Rob and SoxS, have been shown to bind to the mar box; and
constitutive soxS or rob mutants display MDR as well (3, 8).
George and coworkers (2) identified the ramA gene in MDR
Klebsiella pneumoniae and suggested that the MDR phenotype
of this strain was caused by constitutive overexpression of
RamA. Because RamA displays close homology to MarA,
SoxS, and Rob, the suggestion was made that RamA mediates
MDR in Klebsiella via activation of the mar locus. Recently, a
gene identical to ramA was also identified in S. enterica serovar
Paratyphi B and was designated rma (11). In this report, we
describe a gene identical to ramA (rma) in S. enterica serovar
Typhimurium that, when overexpressed on a plasmid in E. coli
which lacks ramA, conferred an MDR phenotype to this bac-
terium and investigate whether this gene has a role in MDR in
S. enterica serovar Typhimurium.
The strains and plasmids used in this study are listed in
Table 1. E. coli marA mutants were kindly provided by S. L.
Levy (6). The MDR S. enterica serovar Typhimurium strains
were obtained from the surveillance collection of CIDC-Lelys-
tad, Lelystad, The Netherlands, and are representatives of
unrelated clinical MDR isolates obtained in The Netherlands
over a 2-year period. The ramA gene was inactivated in these
strains by transduction with a P22 lysate of the ramA::kanamy-
cin Salmonella mutant (10).
To induce expression of RamA, the RamA-coding sequence
was ligated into the isopropyl--D-thiogalactopyranoside (IPTG)-
inducible vector pTrcHisA (Invitrogen) by standard tech-
niques. For constitutive overexpression, ramA was ligated into
pBluescript (Stratagene).
Disk diffusion assays were performed as follows. End-log-
phase bacteria (optical density at 600 nm, 0.8) were diluted
1:10 in phosphate-buffered saline and plated on minimal M9
medium. For E. coli the plates were supplemented with thia-
mine (0.01%) and Casamino Acids (0.1%). If required, ampi-
cillin (50 g/ml) or IPTG (0.1 mM) was added. Cotton disks
containing antibiotics were placed in the centers of the plates.
After overnight incubation at 37°C, the bacterium-free zone
was determined as a measure of resistance. The disk diffusion
assay was used to test the antibiotic susceptibilities of the
bacterial mutant strains, for which the classical MIC broth
microdilution method is not adequate (5).
The MICs for the clinical Salmonella isolates were deter-
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TABLE 1. Salmonella strains and plasmids used in this study
Strain or plasmid Characteristic Origin orreference
S. enterica serovar
Typhimurium
14028s Wild type ATCCa
14028ramA ramA null mutant 10
E. coli
MC1061 Wild type ATCC
AG100 Wild type 6
AG100kana marA 6
Plasmids
pBluescript Cloning vector Stratagene
pB1-ramA Constitutive RamA expression 10
pTrcHisA IPTG-inducible plasmid Invitrogen
pTrcHisA-ramA Inducible RamA expression 10
a ATCC, American Type Culture Collection.
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mined by the broth microdilution method, according to the
NCCLS guidelines (7). An E-test was performed by standard
procedures for determination of tetracycline resistance.
Overexpression of RamA confers MDR in S. enterica serovar
Typhimurium. Given the homology between RamA and MarA
and the findings for Klebsiella and S. enterica serovar Paratyphi
B, we investigated the ability of RamA to confer resistance to
various unrelated antibiotics in S. enterica serovar Typhimu-
rium by means of disk diffusion assays. We induced expression
of RamA in wild-type Salmonella with the IPTG-inducible
ramA plasmid and expressed RamA in E. coli with pBl-ramA.
Both microorganisms displayed an MDR phenotype after over-
expression of RamA (Table 2), which is in accordance with the
published results of George et al. (2) on the expression of
RamA in E. coli. Of note, the latter bacterium lacks ramA, and
we found that ramA is highly confined to S. enterica serovars
(10) and is not present in the genomes of many other members
of the family Enterobacteriaceae, with the notable exceptions of
K. pneumoniae and Enterobacter cloacae.
The MDR phenotype mediated by RamA is independent of
MarA. Yassien et al. (11) showed that RamA (Rma) of S. en-
terica serovar Paratyphi B is a DNA binding protein that binds
to the mar box. MarA is a transcriptional activator for marRAB
and binds to the mar box located within marO. Homologues of
MarA, such as SoxS, Rob, and RamA, have been shown to
bind to the mar box and also to upregulate expression of the
mar locus (3,8,11). Thus, on the basis of experiments with E.
coli, Yassien et al. (11) hypothesized that RamA can substitute
for MarA and directly activate MarA-controlled genes, leading
to an MDR phenotype. An alternative explanation for their
data would be that the MDR phenotype conferred by overex-
pression of RamA is MarA dependent. To investigate this issue
we expressed RamA on an IPTG-inducible multicopy plasmid
in a marA-negative E. coli mutant and its parental strain. As
assessed by disk diffusion assays, in both wild-type E. coli and
the marA-negative mutant, RamA significantly (P  0.025)
increased the levels of resistance to multiple unrelated antibi-
otics and conferred an MDR phenotype (Table 2). This result
demonstrates that in E. coli RamA can mediate an MDR
phenotype independently of a functionally intact marA, likely
by direct activation of MarA-controlled genes.
The antibiotic susceptibility of wild-type Salmonella is not
affected by inactivation of ramA. Next, we assayed the resis-
tance of ramA null mutants of S. enterica serovar Typhimurium
to multiple unrelated antibiotics. These strains were obtained
by gene replacement with suicide vector pGP704, which con-
tains ramA inactivated by a kanamycin cassette (10). Com-
pared with the wild-type parental Salmonella strain, the null
mutants did not display increased susceptibilities to tetracy-
cline, chloramphenicol, ciprofloxacin, or nalidixic acid (Table
2). The identical susceptibilities of the Salmonella strains to,
for instance, ciprofloxacin were confirmed by E-test on Iso-
Sensitest agar plates, with the MICs for all strains being 0.032
to 0.064 mg/liter.
The MDR phenotype of clinical isolates of Salmonella is not
affected by inactivation of ramA. Further evidence that a func-
tionally intact ramA is dispensable for the expression of an
MDR phenotype was obtained in experiments with 15 clinical
S. enterica serovar Typhimurium isolates (including strain 12
DT104), all of which displayed an MDR phenotype, as de-
fined by resistance to at least three unrelated antibiotics. These
strains were obtained from the Dutch national surveillance
collection of CIDC-Lelystad and are representative of unre-
lated clinical MDR isolates obtained in The Netherlands over
a 2-year period. In these strains the ramA gene was inactivated
by transduction with a P22 lysate of the ramA::kanamycin Sal-
monella mutant. The MDR phenotype was not reversed to a
non-MDR, susceptible phenotype in any of these strains (Ta-
ble 3), as determined by assays for MICs. In more than 270
assays for MICs, only 2 indicated a change in the MIC of more
than 2 dilution steps by the broth microdilution method, ac-
cording to the NCCLS guidelines (7). The MICs of doxycy-
cline, tetracycline, and florfenicol for six MDR strains showed
slight decreases; however, according to the NCCLS guidelines,
the interpretation of the final MICs still indicated a resistant
phenotype.
In conclusion, overexpression of RamA in E. coli and S.
enterica serovar Typhimurium confers an MDR phenotype in a
MarA-independent manner that is likely mediated by direct
activation of mar-regulated genes, although formal proof for
this is not yet available. However, inactivation of ramA does
not lead to enhanced antibiotic susceptibility and does not
reverse the antibiotic resistance phenotypes of 15 unrelated
clinical MDR S. enterica serovar Typhimurium isolates. Thus,
TABLE 2. Antibiotic susceptibilities of E. coli and S. enterica
serovar Typhimurium strains
Strain
Zone of inhibition (mm)a
NAL CIP CHL TET GEN
S. enterica serovar Typhimurium
14028s 40  1 48  2 41 1 42 2 NDd
14028s ramA 38 1 47  2 40 1 42 2 ND
14028s  pTrcHisA-ramAb
No IPTG 21  1 40  2 29 1 37 1 ND
IPTG added 15  1 33  1 12 2 30 2 ND
E. coli
MC1061  pB1c ND 42  2 30 2 ND ND
MC1061  pB1-ramA ND 32  1 24 2 ND ND
AG100 23  1 39  1 35 1 31 1 30  1
AG100kana (marA::kan) 23  1 41  2 35 1 30 1 30  1
AG100  pHisA-ramA
No IPTG 21  1 39  1 34 1 30 1 30  1
IPTG added 15  1 36  1 21 2 27 1 30  1
AG100kana (marA::kan) 
pHisA-ramA
No IPTG 23  1 40  1 34 2 30 1 30  1
IPTG added 17  1 33  1 22 1 25 1 30  1
a Zones of growth inhibition around cotton disks (diameters, 6 mm) were
determined by the disk diffusion assay on standardized M9 minimal medium agar
plates; the following dosages were added to the disks: nalidixic acid (NAL), 130
g; ciprofloxacin (CIP) 10 g; chloramphenicol (CHL), 300 g; tetracycline
(TET), 80 g; gentamicin (GEN), 100 g. The (CIP), mean and standard devi-
ations of four independent experiments are given.
b ramA gene expressed on IPTG-inducible plasmid pTrcHisA (Invitrogen).
c pB1, plasmid pBluescript.
d ND, not done.
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the findings for Salmonella rule against a common role of this
gene in the MDR phenotypes of clinical Salmonella isolates.
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TABLE 3. MICs for MDR S. enterica serovar Typhimurium strains and their ramA knock-out mutants
Salmonella
strain
MIC (mg/liter)
Amoxicillin Gentamicin Doxycycline Trimethoprim Tetracycline Flumequine Ciprofloxacin Florfenicol Chloramphenicol
14028s 1 1 2 0.5 1 0.5 0.06 4 8
14028s ramA 1 1 2 0.5 1 0.5 0.06 4 8
MDR strains
1 32 0.25 16 0.5 32 0.5 0.03 128 128
1 ramA 32 0.5 16 0.5 24 0.5 0.06 64 128
2 32 0.25 16 64 256 1 0.06 128 128
2 ramA 32 0.5 8 64 48 0.5 0.06 32 128
3 32 0.5 16 0.5 96 0.5 0.03 128 128
3 ramA 32 0.5 4 0.5 24 0.5 0.06 64 128
4 32 0.25 16 0.5 32 1 0.03 32 128
4 ramA 32 1 8 0.5 24 0.5 0.06 32 128
5 32 0.25 16 1 256 2 0.06 64 128
5 ramA 32 0.25 8 0.5 24 0.5 0.06 16 128
6 32 0.5 16 0.5 32 1 0.03 32 128
6 ramA 32 0.25 4 0.5 32 0.5 0.06 32 128
7 32 0.25 16 0.5 48 0.5 0.03 32 128
7 ramA 32 0.5 4 0.5 16 0.5 0.06 16 128
8 32 0.5 16 0.5 48 0.5 0.03 32 128
8 ramA 32 0.5 8 0.5 24 0.5 0.06 16 128
9 32 0.5 16 0.5 96 0.5 0.03 32 128
9 ramA 32 0.5 4 0.5 24 0.5 0.06 32 128
10 32 0.5 64 64 256 0.5 0.03 2 128
10 ramA 32 0.5 32 64 256 1 0.06 4 128
11 32 0.25 32 0.5 256 64 4 4 128
11 ramA 32 0.5 32 0.5 256 32 8 4 128
12 32 0.25 16 0.5 48 0.5 0.03 64 128
12 ramA 32 0.5 8 0.5 32 0.5 0.06 16 128
13 32 0.5 32 64 256 0.5 0.03 4 128
13 ramA 32 0.5 32 64 256 0.5 0.06 4 128
14 32 0.25 16 0.5 96 1 0.03 64 128
14 ramA 32 0.5 16 0.5 128 0.5 0.06 32 128
15 32 0.25 16 0.5 32 0.5 0.03 64 128
15 ramA 32 0.5 8 0.5 24 1 0.06 32 128
a According to NCCLS guideline M2-A7, the MIC breakpoints are as follows: for amoxicillin (the criteria for ampicillin were used), sensitive, 8 mg/liter; resistant,
32 mg/liter; for gentamicin, sensitive, 4 mg/liter; resistant, 8 mg/liter; for doxycycline, sensitive, 4 mg/liter; resistant, 16 mg/liter; for flumequine (the criteria
for oxolinic acid were used), sensitive, 4 mg/liter; resistant, 8 mg/liter; for tetracycline, sensitive, 4 mg/liter; resistant, 16 mg/liter (values for tetracycline were
determined by E-test); for ciprofloxacin, sensitive, 2 mg/liter; resistant, 4 mg/liter; for chloramphenicol, sensitive, 64 mg/liter; resistant, 128 mg/liter. According
to NCCLS guideline M31-A2, MIC breakpoints for florfenicol are as follows: sensitive, 2 mg/liter; resistant, 8 mg/liter.
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